CDTX
Price
$88.62
Change
+$15.13 (+20.59%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
1.86B
NRXP
Price
$2.99
Change
+$0.14 (+4.91%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
67.74M
Interact to see
Advertisement

CDTX vs NRXP

Header iconCDTX vs NRXP Comparison
Open Charts CDTX vs NRXPBanner chart's image
Cidara Therapeutics
Price$88.62
Change+$15.13 (+20.59%)
Volume$26.83K
Capitalization1.86B
NRX Pharmaceuticals
Price$2.99
Change+$0.14 (+4.91%)
Volume$2.62K
Capitalization67.74M
CDTX vs NRXP Comparison Chart in %
Loading...
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NRXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDTX vs. NRXP commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDTX is a Buy and NRXP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (CDTX: $73.49 vs. NRXP: $2.85)
Brand notoriety: CDTX and NRXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDTX: 135% vs. NRXP: 84%
Market capitalization -- CDTX: $1.86B vs. NRXP: $67.74M
CDTX [@Biotechnology] is valued at $1.86B. NRXP’s [@Biotechnology] market capitalization is $67.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDTX’s FA Score shows that 0 FA rating(s) are green whileNRXP’s FA Score has 0 green FA rating(s).

  • CDTX’s FA Score: 0 green, 5 red.
  • NRXP’s FA Score: 0 green, 5 red.
According to our system of comparison, NRXP is a better buy in the long-term than CDTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDTX’s TA Score shows that 4 TA indicator(s) are bullish while NRXP’s TA Score has 4 bullish TA indicator(s).

  • CDTX’s TA Score: 4 bullish, 4 bearish.
  • NRXP’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CDTX is a better buy in the short-term than NRXP.

Price Growth

CDTX (@Biotechnology) experienced а +13.57% price change this week, while NRXP (@Biotechnology) price change was -4.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDTX($1.86B) has a higher market cap than NRXP($67.7M). CDTX YTD gains are higher at: 173.400 vs. NRXP (29.545). NRXP has higher annual earnings (EBITDA): -33.79M vs. CDTX (-208.92M). CDTX has more cash in the bank: 511M vs. NRXP (2.91M). CDTX has less debt than NRXP: CDTX (2.33M) vs NRXP (10.2M). CDTX (0) and NRXP (0) have equivalent revenues.
CDTXNRXPCDTX / NRXP
Capitalization1.86B67.7M2,753%
EBITDA-208.92M-33.79M618%
Gain YTD173.40029.545587%
P/E RatioN/A0.36-
Revenue00-
Total Cash511M2.91M17,560%
Total Debt2.33M10.2M23%
FUNDAMENTALS RATINGS
CDTX vs NRXP: Fundamental Ratings
CDTX
NRXP
OUTLOOK RATING
1..100
1368
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
98100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3443
P/E GROWTH RATING
1..100
10093
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NRXP's Valuation (52) in the null industry is somewhat better than the same rating for CDTX (85) in the Biotechnology industry. This means that NRXP’s stock grew somewhat faster than CDTX’s over the last 12 months.

CDTX's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as NRXP (100) in the null industry. This means that CDTX’s stock grew similarly to NRXP’s over the last 12 months.

CDTX's SMR Rating (97) in the Biotechnology industry is in the same range as NRXP (100) in the null industry. This means that CDTX’s stock grew similarly to NRXP’s over the last 12 months.

CDTX's Price Growth Rating (34) in the Biotechnology industry is in the same range as NRXP (43) in the null industry. This means that CDTX’s stock grew similarly to NRXP’s over the last 12 months.

NRXP's P/E Growth Rating (93) in the null industry is in the same range as CDTX (100) in the Biotechnology industry. This means that NRXP’s stock grew similarly to CDTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDTXNRXP
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
85%
Bullish Trend 16 days ago
82%
Declines
ODDS (%)
Bearish Trend 17 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CDTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NRXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SVUIX40.690.01
+0.02%
NAA SMid Cap Value Institutional
OPMIX35.92-0.08
-0.22%
Invesco Main Street Mid Cap R6
RRCOX64.82-0.37
-0.57%
T. Rowe Price U.S. Equity Research R
BMIDX18.28-0.12
-0.65%
Brown Advisory Mid-Cap Growth Investor
ESGCX20.08-0.15
-0.74%
Mirova Global Megatrends C

CDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDTX has been closely correlated with NBY. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if CDTX jumps, then NBY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDTX
1D Price
Change %
CDTX100%
-2.62%
NBY - CDTX
93%
Closely correlated
+1.42%
NCNA - CDTX
93%
Closely correlated
-2.99%
TAOX - CDTX
93%
Closely correlated
-2.90%
BPTSY - CDTX
92%
Closely correlated
N/A
KPRX - CDTX
90%
Closely correlated
-2.68%
More

NRXP and

Correlation & Price change

A.I.dvisor indicates that over the last year, NRXP has been closely correlated with CDTX. These tickers have moved in lockstep 85% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRXP
1D Price
Change %
NRXP100%
-0.70%
CDTX - NRXP
85%
Closely correlated
-2.62%
NCNA - NRXP
84%
Closely correlated
-2.99%
RNAC - NRXP
83%
Closely correlated
-2.29%
ALLR - NRXP
83%
Closely correlated
-10.11%
TAOX - NRXP
82%
Closely correlated
-2.90%
More